Congratulations to MCB Professor Susan Marqusee for becoming a 2019 Miller Senior Fellow! The fellowship supports excellence in science at UC Berkeley by enhancing interactions among Miller Institute Fellows, all of whom are accomplished and distinguished scientists in their field. It also provides significant discretionary funds for research.
Below are articles from various sources about members of MCB and their research.
MCB has been busy!
Learn about our recent research endeavors, read about the new CRISPR course, catch up on community happenings, and much more...
The Immunotherapeutics and Vaccine Research Initiative (IVRI) is partnering with Aduro Biotech to fund exploration into new cures for cancers and infectious diseases.
“It’s a successful example of private academic with public industry partnership… We managed to generate a really good platform for research,” said Julia Schaletzky, Executive Director of IVRI.
MCB Professor David Raulet serves as Faculty Director of IVRI. According to Raulet, the partnership is unique for two reasons: it unites infectious disease researchers and cancer immunologists, and it funds basic science instead of research into particular cancers or diseases.
On November 5, UC Berkeley hosted the 2019 Breakthrough Prize Symposium. The event hosts talks from some of the world's brightest minds at the forefront of fundamental physics, life sciences and mathematics.
Professor of MCB & Chemistry Jennifer Doudna, recipient of the 2015 Breakthrough Prize in life sciences, spoke on recent breakthroughs in CRISPR research. Her presentation, titled Recoding Life: The Future of Gene Editing, can be viewed here.
MCB Professor Daniel Rokhsar has been appointed to the Marthella Foskett Brown Chair in Biological Sciences. The Chair supports faculty research in quantitative and systems biology.
Congratulations to MCB & Chemistry Professor Jennifer Doudna, who is one of five recipients of this year's Medal of Honor from the American Cancer Society! Medal of Honor recipients are "distinguished individuals who have made valuable contributions in the fight against cancer through basic research, clinical research and cancer control."
Professor Doudna joined four others in receiving the award at a ceremony today in Washington, DC: former Vice President Joe Biden, CRISPR co-inventor Emmanuelle Charpentier, geneticist Charis Eng, and cancer researcher Michael Thun.
Two new publications from MCB Professor David Raulet and collaborators focus on the role of natural killer cells in anti-tumor responses. Natural killer cells are a type of white blood cell that have an important role in defending against virally infected cells and tumors.
The first, published in Journal of Clinical Investigation, demonstrated that checkpoint inhibitors, a well-established cancer immunotherapy, have the ability to activate natural killer cells. In the future, researchers hope to better understand the factors that influence natural killer cell activation for use in improved immunotherapies. Read more...
The second paper, published in Immunity, is a collaboration with the lab of MCB Professor Russell Vance. It shows that cGAMP from tumors promotes natural killer anti-tumor immune responses. Read more...
A new paper from the lab of Professor of MCB & Chemistry and HHMI Investigator Jennifer Doudna identifies and details the power of the smallest CRISPR system found to date, Cas14. CRISPR-Cas14 was first discovered in archaea with some of the smallest known genomes and is especially effective in editing viral genes or genes in small cells.
Due to its effectiveness in targeting and cutting single-stranded DNA, researchers have identified Cas14's potential use in improving rapid CRISPR diagnostic tests for ailments such as cancer and infectious diseases.
A new paper by Professor of the Graduate School Bruce Ames, published in Proceedings of the National Academy of Science, argues that a set of vitamins and minerals that are lacking from many Americans' diets may be key to defending against many chronic diseases and promoting healthy aging.
The publication is the culmination of a decade of research completed at Children's Hospital Oakland Research Institute (CHORI) and "concludes that healthy aging can be extended by ingesting optimal levels of 30 known vitamins and essential minerals, and he suggests that these, along with 11 additional substances not currently classified as vitamins, should be recognized as essential 'longevity vitamins' because of their potential to extend a healthy life."
MCB Professors and HHMI Investigators John Kuriyan and Barbara Meyer have been elected to the National Academy of Medicine, which recognizes researchers who have made major contributions to the advancement of medical sciences, health care, and public health.
Kuriyan has been recognizes for his work in understanding eukaryotic cell signaling regulation, and Meyer for her work on chromosome dynamics.
MCB Postdoc Polina Kosillo has been awarded a NARSAD Young Investigator grant from the Brain & Behavior Research Foundation. The grant provides up to $70,000 over 2 years to promising young neurobiology researchers who study brain & behavioral disorders.
Kosillo studies the impact of dopamine dysfunction on mental disorders, such as ADHD and anxiety disorders. She is a member of the lab of MCB Assistant Professor Helen Bateup.
On September 28, the MCB community hosted representatives from nine major Bay Area biotechnology companies for the second annual Fall 2018 Industrial Affiliates Program (IAP) Symposium. The event was a great success, drawing approximately 100 students and postdoctoral scholars from several departments on campus including MCB, Bioengineering, Biostatistics, Biophysics, and Chemistry.
MCB Assistant Adjunct Professor Denis Titov is a 2018 recipient of the NIH Director's New Innovator award, which funds high-impact research from "extraordinarily creative scientists." The New Innovator award specifically supports early career researchers carrying out highly innovative biomedical research.
Titov joined the MCB Department in 2018. His research focuses on aging and age-associated diseases.
Immunologist James P. Allison shares the 2018 Nobel Prize in Physiology or Medicine with Tasuku Honjo of Kyoto University “for their discovery of cancer therapy by inhibition of negative immune regulation.”
Allison performed the basic research that revolutionized immunotherapy for use in treating cancer at UC Berkeley, where he was a Professor of Immunology and the director of the Cancer Research Laboratory from 1985 to 2004.
"This award is a testament to the incredible impact that the fundamental research Jim conducted at Berkeley has had on the lives of cancer patients," said MCB Professor Russell Vance, current director of the Cancer Research Laboratory.